Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of alkalising treatments in cystinuria
2017-002068-42Phase 3Terminated
- Sponsor
- Advicenne
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of Sibnayal in cystinuria (CSNU) (2 cohorts), sponsored by Advicenne. Primary endpoint: Treatment-emergent adverse events. Started Jun 2018; status: terminated.
02
Drugs
Sibnayal
03
Conditions
cystinuria (CSNU)
Beyond the preview
Go deeper on 2017-002068-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002068-42.